Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. (Q45941383)
Jump to navigation
Jump to search
scientific article published on 26 July 2011
Language | Label | Description | Also known as |
---|---|---|---|
English | Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. |
scientific article published on 26 July 2011 |
Statements
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung (English)
Gilberto de Lima Lopes
Daniel S W Tan
Young K Do
Eric A Finkelstein
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference